The European Medicines Agency said an eye condition that might cause loss of vision is a very rare side effect of Novo Nordisk's blockbuster drugs Ozempic and Wegovy.

Dr. Shervin Naderi and his team integrate facial rejuvenation with weight loss care to manage the structural facial changes ...

Omada is trading publicly after 14 years of providing support to patients with weight-related chronic illnesses. Leadership sees the current moment as the perfect time for an IPO, as GLP-1 drugs such ...

Weight-loss drugs are already dropping in price; could they go even lower? - Consumers are now able to pay roughly $500 for ...